Valuation: Haleon plc

Capitalization 32.41B 43.37B 37.37B 34.8B 60.35B 3,931B 64.9B 400B 158B 1,876B 162B 159B 6,855B P/E ratio 2025 *
21x
P/E ratio 2026 * 19.5x
Enterprise value 39.94B 53.45B 46.05B 42.88B 74.38B 4,844B 79.99B 493B 194B 2,313B 200B 196B 8,448B EV / Sales 2025 *
3.61x
EV / Sales 2026 * 3.4x
Free-Float
89.25%
Yield 2025 *
1.93%
Yield 2026 * 2.17%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.47%
1 week-0.98%
Current month-2.91%
1 month+0.14%
3 months+5.45%
6 months+1.08%
Current year-2.91%
More quotes
1 week 358.9
Extreme 358.9
371
1 month 358.9
Extreme 358.9
380.8
Current year 358.9
Extreme 358.9
380.8
1 year 274.4
Extreme 274.4
419.5
3 years 274.4
Extreme 274.4
419.5
5 years 241.17
Extreme 241.1735
419.5
10 years 241.17
Extreme 241.1735
419.5
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 2021-07-21
Director of Finance/CFO 56 2024-10-31
Chief Tech/Sci/R&D Officer 63 2025-07-31
Director TitleAgeSince
Director/Board Member 59 2022-05-22
Chairman 71 2025-12-31
Director/Board Member 58 2022-07-17
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.47%-0.98%-1.57%+12.31% 43.38B
+0.53%-2.37%+37.06%+187.15% 930B
-0.41%+6.98%+47.97%+26.08% 527B
-0.31%-2.60%+23.40%+39.55% 379B
+0.93%+2.38%+29.90%+18.43% 371B
+0.19%-1.15%+29.58%+20.35% 292B
-1.93%-1.54%+8.07%-3.05% 270B
+0.98%+1.37%+27.61%+34.08% 276B
+6.49%+1.95%-35.37%-18.36% 268B
+0.12%+1.32%+22.63%+21.59% 178B
Average +0.71%+0.54%+18.93%+33.81% 353.43B
Weighted average by Cap. +0.59%+0.49%+26.20%+63.25%
See all sector performances

Financials

2025 *2026 *
Net sales 11.07B 14.81B 12.76B 11.89B 20.61B 1,343B 22.17B 137B 53.84B 641B 55.49B 54.41B 2,342B 11.55B 15.46B 13.32B 12.4B 21.51B 1,401B 23.13B 143B 56.17B 669B 57.9B 56.77B 2,443B
Net income 1.58B 2.11B 1.82B 1.7B 2.94B 192B 3.16B 19.51B 7.69B 91.51B 7.92B 7.77B 334B 1.69B 2.26B 1.94B 1.81B 3.14B 204B 3.38B 20.81B 8.2B 97.61B 8.45B 8.29B 357B
Net Debt 7.53B 10.08B 8.68B 8.09B 14.03B 914B 15.08B 92.98B 36.64B 436B 37.76B 37.02B 1,593B 6.89B 9.22B 7.95B 7.4B 12.83B 836B 13.8B 85.08B 33.52B 399B 34.55B 33.88B 1,458B
More financial data * Estimated data
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (29.5%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (22.8%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (17.7%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - vitamins, minerals and food supplements (15.1%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. - respiratory medicines (14.9%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.2%), North America (36%), and Asia/Pacific (22.8%).
Employees
24,561
More about the company
Date Price Change Volume
26-01-16 363.90 p +0.47% 16,515,550
26-01-15 362.20 p -1.07% 11,809,150
26-01-14 366.10 p +1.02% 21,599,440
26-01-13 362.40 p +0.06% 12,660,110
26-01-12 362.20 p -1.44% 14,599,970

Delayed Quote London S.E., January 16, 2026 at 11:35 am EST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.639GBP
Average target price
4.178GBP
Spread / Average Target
+14.80%
Consensus

Quarterly revenue - Rate of surprise